Carl Zeiss Meditec AG (XSWX:AFX) Future 3-5Y EPS without NRI Growth Rate: N/A (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
78 GF Score
Price CHF29.36
GF Value CHF71.65
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Carl Zeiss Meditec AG's Future 3-5Y EPS without NRI Growth Rate is N/A.

Carl Zeiss Meditec AG  (XSWX:AFX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Carl Zeiss Meditec AG Future 3-5Y EPS without NRI Growth Rate Related Terms

XSWX:AFX vs ISRG, BDX, RMD: Future 3-5Y EPS without NRI Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Future 3-5Y EPS without NRI Growth Rate falls into.


XSWX:AFX
78GF Score
Carl Zeiss Meditec AG XSWX:AFX
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF29.36 is trading 59% below its estimated GF Value™ of CHF71.65.

Key valuation signals for XSWX:AFX:

  • Future 3-5Y EPS without NRI Growth Rate: N/A
  • GF Value™: CHF71.65 vs. price of CHF29.36 (59% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
78GF Score

Get the complete analysis for XSWX:AFX

Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF29.36
Price
CHF71.65
GF Value